TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22248761

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia with bupivacaine and epidural morphine
Number of subjects: 80

Group type: COMPARATOR
Intervention: NSAIDs and intravenous morphine
Number of subjects: 80
Study: 20658749

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy interruption
Number of subjects: 332

Group type: COMPARATOR
Intervention: Antiretroviral therapy continuation
Number of subjects: 332
Study: 18845605

Group type: EXPERIMENTAL
Intervention: Goal setting and individualised activities of daily living activity programme by a gerontology nurse, reinforced by usual healthcare assistants
Number of subjects: 682

Group type: COMPARATOR
Intervention: Social visits
Number of subjects: 682
Study: 16117862

Group type: EXPERIMENTAL
Intervention: Intracoronary injection of bone‐marrow cells (BMCs)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Diluted serum (control)
Number of subjects: 20
Study: 12842060

Group type: EXPERIMENTAL
Intervention: Sutured group
Number of subjects: 74

Group type: COMPARATOR
Intervention: Not sutured group
Number of subjects: 74
Study: 11057001

Group type: EXPERIMENTAL
Intervention: Orthographic cues
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination of orthographic and phonological cues
Number of subjects: 0
Study: 8853729

Group type: EXPERIMENTAL
Intervention: 60 mg beta-carotene orally three times daily and multivitamins
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo and multivitamins
Number of subjects: 72
Study: 1353367

Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atenolol 100 mg once daily
Number of subjects: 0
Study: 6391665

Group type: EXPERIMENTAL
Intervention: Stuart Prenatal tablets
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Stuart-natal 1 + 1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Materna
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31487577

Group type: EXPERIMENTAL
Intervention: Behavioral treatment for cannabis use disorder (CUD) over 9 sessions
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Behavioral treatment for cannabis use disorder (CUD)
Number of subjects: 198
Study: 29270622

Group type: EXPERIMENTAL
Intervention: External Vibration Therapy (EVT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 26762883

Group type: EXPERIMENTAL
Intervention: Concise care
Number of subjects: 182

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 182
Study: 24842917

Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 19

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 19
Study: 21976631

Group type: EXPERIMENTAL
Intervention: Low-dose CT (LDCT)
Number of subjects: 1406

Group type: EXPERIMENTAL
Intervention: Further investigations (FDG-PET or CT-guided FNAB)
Number of subjects: 1406

Group type: EXPERIMENTAL
Intervention: Risk assessment based on radiation exposure
Number of subjects: 1406
Study: 20852060

Group type: EXPERIMENTAL
Intervention: Exercise training (ET) 3 days per week for 16 weeks
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Exercise training (ET)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Attention control (biweekly follow‐up telephone calls)
Number of subjects: 53
Study: 17664342

Group type: EXPERIMENTAL
Intervention: Arthroscopic Bankart repair
Number of subjects: 60

Group type: COMPARATOR
Intervention: Open Bankart repair
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 16338450

Group type: EXPERIMENTAL
Intervention: RTS,S/AS02A vaccine
Number of subjects: 2022
Study: 12222942

Group type: EXPERIMENTAL
Intervention: Limited approach
Number of subjects: 65

Group type: COMPARATOR
Intervention: Extended approach
Number of subjects: 65
Study: 10812681

Group type: EXPERIMENTAL
Intervention: Aprotinin (100,000 KIU) applied locally to the wound surface after IMA harvesting in group C1
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Aprotinin (500,000 KIU) applied locally to the wound surface and into the pericardial cavity in group D1
Number of subjects: 275

Group type: COMPARATOR
Intervention: Venous grafts in group A2
Number of subjects: 275

Group type: COMPARATOR
Intervention: IMA used in group B2
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Aprotinin (500,000 KIU) in group D2
Number of subjects: 275
Study: 7726440

Group type: EXPERIMENTAL
Intervention: Propofol infusion (2.4 +/- 0.7 mg.kg‐1.h‐1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Midazolam infusion (0.13 +/- 0.04 mg.kg‐1.h‐1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Single nonsedating bolus dose propofol (0.4 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal saline infusion
Number of subjects: 10
Study: 1768821

Group type: EXPERIMENTAL
Intervention: Various strategies to manage cardiopulmonary bypass (hypothermia vs normothermia, presence vs absence of arterial microfilters, presence vs absence of glucose-containing solution in pump prime)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical procedure and management of cardiopulmonary bypass
Number of subjects: 0
Study: 6120738

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg twice daily)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Ranitidine (open assessment)
Number of subjects: 42
Study: 31774340

Group type: EXPERIMENTAL
Intervention: Various interventions across trials
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 30336812

Group type: EXPERIMENTAL
Intervention: iFR
Number of subjects: 2037

Group type: COMPARATOR
Intervention: FFR
Number of subjects: 2037
Study: 26743498

Group type: EXPERIMENTAL
Intervention: NIRS-visible group (crSO2 monitoring)
Number of subjects: 60

Group type: COMPARATOR
Intervention: NIRS-not-visible group (only pulse oximetry)
Number of subjects: 60
Study: 23435350

Group type: EXPERIMENTAL
Intervention: Recreational Music Making (RMM)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Quiet reading
Number of subjects: 34
Study: 21671126

Group type: EXPERIMENTAL
Intervention: Curcumin
Number of subjects: 50
Study: 18340278

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (50 mug/day)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (50 mug/day) plus medroxyprogesterone acetate (5 mg/day)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Oral estradiol (2 mg/day)
Number of subjects: 61
Study: 16426255

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 12940397

Group type: EXPERIMENTAL
Intervention: Stress Inoculation Training
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Hypnotic Stress Inoculation Training
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Nonhypnotic analgesia suggestions
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Hypnotic analgesia suggestions
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Hypnotic induction treatment
Number of subjects: 285

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 285
Study: 10901102

Group type: EXPERIMENTAL
Intervention: Gd-DTPA-BMEA (OptiMARK)
Number of subjects: 395

Group type: COMPARATOR
Intervention: Gd-DTPA (Magnevist)
Number of subjects: 395
Study: 9358478

Group type: EXPERIMENTAL
Intervention: Coated IPGs
Number of subjects: 39

Group type: COMPARATOR
Intervention: Uncoated IPGs
Number of subjects: 39
Study: 1589071

Group type: EXPERIMENTAL
Intervention: 1 mg clebopride administered iv after surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 3803414

Group type: EXPERIMENTAL
Intervention: Oral verapamil (Isoptin) b.d. or t.d.s. (240, 360 or 480 mg daily)
Number of subjects: 12
Study: 30068784

Group type: EXPERIMENTAL
Intervention: T-stenting
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Mini-crush
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Culotte
Number of subjects: 238
Study: 27759644

Group type: EXPERIMENTAL
Intervention: Oxycontin and gabapentin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oxycontin and placebo
Number of subjects: 60
Study: 24495617

Group type: EXPERIMENTAL
Intervention: Leuprolide (1mg daily sc injections for 4 days in the 1st and 3rd weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nandrolone decanoate (ND) co-administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Urine leuprolide and M1 measurement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screening using urine steroid and LH measurements
Number of subjects: 0
Study: 23210198

Group type: EXPERIMENTAL
Intervention: Corticotomy-facilitated orthodontic tooth movement (CFO)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional orthodontic therapy
Number of subjects: 20
Study: 20671206

Group type: COMPARATOR
Intervention: Individualized oral hygiene instruction (OHI)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: OHI and applications of 1% chlorhexidine varnish every 3 months
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: OHI and applications of 5% sodium fluoride varnish every 3 months
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: OHI and annual applications of 38% silver diamine fluoride (SDF) solution
Number of subjects: 306
Study: 19007071

Group type: EXPERIMENTAL
Intervention: 0.02 tapered gutta‐percha using System B for downpack and Obtura II for backfilling
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.06 tapered gutta‐percha using System B for downpack and Obtura II for backfilling
Number of subjects: 40
Study: 18701006

Group type: EXPERIMENTAL
Intervention: Sublingual specific immunotherapy (SLIT), treated daily for at least two consecutive years.
Number of subjects: 305

Group type: COMPARATOR
Intervention: Control group (never treated with specific immunotherapy).
Number of subjects: 305
Study: 15155200

Group type: EXPERIMENTAL
Intervention: Extended-release (XR) formulation of ciprofloxacin (1,000 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate-release (IR) formulation of ciprofloxacin (1,000 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of XR and IR formulations at MIC of 0.5 mg/liter
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of XR and IR formulations at MICs of 0.03 and 2.0 mg/liter
Number of subjects: 0
Study: 11465169

Group type: EXPERIMENTAL
Intervention: Conventional antibiotic prophylaxis (ceftriaxone 2 g on postoperative day 1)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Prolonged antibiotic prophylaxis (ticarcillin + clavulanic acid 3 x 5.2 g during 72 hours)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Untreated positive patients
Number of subjects: 500

Group type: COMPARATOR
Intervention: Untreated negative patients
Number of subjects: 500
Study: 9236440

Group type: EXPERIMENTAL
Intervention: Clonidine 2 micrograms/kg IV (n = 15)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.9% normal saline (n = 5)
Number of subjects: 20
Study: 8232945

Group type: EXPERIMENTAL
Intervention: Gabapentin (600, 1,200, or 1,800 mg/d)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 306
Study: 3631784

Group type: EXPERIMENTAL
Intervention: Desmopressin (10 micrograms/m2)
Number of subjects: 35
Study: 30582774

Group type: EXPERIMENTAL
Intervention: INS/DAPA (Insulin + Dapagliflozin 5 mg/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: INS (Basal-bolus insulin titration algorithm)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: INS/DAPA
Number of subjects: 18

Group type: COMPARATOR
Intervention: INS
Number of subjects: 18
Study: 28432077

Group type: EXPERIMENTAL
Intervention: 6-month, 3×/week aerobic training
Number of subjects: 21

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 21
Study: 27103371

Group type: EXPERIMENTAL
Intervention: Normoglycemia for 4h
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: GLP-1 infusion for 4h
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combination of normoglycemia and GLP-1 for 4h
Number of subjects: 15

Group type: COMPARATOR
Intervention: Hyperglycemia plus GLP-1 infusion for 4h
Number of subjects: 15
Study: 25579357

Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% eye drops once daily for 4 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Brimonidine 0.2% eye drops twice daily for 4 weeks
Number of subjects: 40
Study: 21722178

Group type: EXPERIMENTAL
Intervention: ESD with a balloon wedged in the bulbus duodeni (balloon [+] group)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional ESD with no balloon (balloon [-] group)
Number of subjects: 16
Study: 19996339

Group type: EXPERIMENTAL
Intervention: Tobramycin inhalation solution (TIS) 300 mg/5 ml twice daily for 28 days
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Tobramycin inhalation solution (TIS) 300 mg/5 ml twice daily for 56 days
Number of subjects: 88

Group type: COMPARATOR
Intervention: Tobramycin inhalation solution (TIS) 300 mg/5 ml twice daily for 28 days (control group)
Number of subjects: 88
Study: 17934393

Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg/d
Number of subjects: 0
Study: 16371799

Group type: EXPERIMENTAL
Intervention: Kinesthesia and balance exercises in addition to strengthening exercises
Number of subjects: 66

Group type: COMPARATOR
Intervention: Strengthening exercises only
Number of subjects: 66
Study: 12088975

Group type: EXPERIMENTAL
Intervention: Dexamethasone 5 mg IV
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tropisetron 2 mg IV
Number of subjects: 120

Group type: COMPARATOR
Intervention: Saline (Placebo)
Number of subjects: 120
Study: 10218187

Group type: EXPERIMENTAL
Intervention: Therapy dog
Number of subjects: 0
Study: 8574128

Group type: EXPERIMENTAL
Intervention: Clemastine fumarate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 2669440

Group type: EXPERIMENTAL
Intervention: 300 mg moclobemide
Number of subjects: 62

Group type: COMPARATOR
Intervention: 150 mg clomipramine
Number of subjects: 62
Study: 1095963

Group type: EXPERIMENTAL
Intervention: S-adenosylmethionine (SAMe) intravenously administered for 20 days at two daily doses of 15 mg
Number of subjects: 70

Group type: COMPARATOR
Intervention: Fructose-1-6-diphosphate sodium salt intravenously administered for 20 days at two daily doses of 2.5 mg
Number of subjects: 70
Study: 30616009

Group type: EXPERIMENTAL
Intervention: MultiPoint Pacing (MPP) programmed to mandated MPP‐AS settings
Number of subjects: 5000

Group type: COMPARATOR
Intervention: Continued BiV pacing
Number of subjects: 5000
Study: 28679495

Group type: EXPERIMENTAL
Intervention: Vaccine containing 120 μg sF with 5 μg GLA in SE
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Vaccine containing 120 μg sF with 2.5 μg GLA in SE
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Vaccine containing 80 μg sF with 2.5 μg GLA in SE
Number of subjects: 261

Group type: COMPARATOR
Intervention: Inactivated influenza vaccine (IIV)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261
Study: 26522175

Group type: EXPERIMENTAL
Intervention: COPE Healthy Lifestyles TEEN Program
Number of subjects: 779

Group type: COMPARATOR
Intervention: Healthy Teens (attention control program)
Number of subjects: 779
Study: 23003920

Group type: EXPERIMENTAL
Intervention: Surgical stripping
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Er:YAG laser (180 mJ, 10 Hz, long pulse)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: CO2 laser (2 to 4 W, continuous wave)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Er:YAG laser
Number of subjects: 35

Group type: COMPARATOR
Intervention: Comparison of all treatments
Number of subjects: 35
Study: 22003347

Group type: EXPERIMENTAL
Intervention: Algorithmic internet-based intervention alone
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Algorithmic internet-based intervention in combination with a prescribed bedtime routine
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 171
Study: 19322730

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 17578981

Group type: EXPERIMENTAL
Intervention: TEA with ropivacaine and sufentanil
Number of subjects: 68

Group type: COMPARATOR
Intervention: IV morphine
Number of subjects: 68
Study: 15628811

Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 421

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 421
Study: 15159244

Group type: EXPERIMENTAL
Intervention: CLA-triacylglycerol
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: CLA-FFA
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: CLA (both groups)
Number of subjects: 180

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 180
Study: 11176493

Group type: EXPERIMENTAL
Intervention: Percutaneous sacral nerve root neuromodulation
Number of subjects: 15
Study: 9403147

Group type: EXPERIMENTAL
Intervention: Additional information (high or low in distinctiveness, consistency, and consensus)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 0
Study: 8501476

Group type: EXPERIMENTAL
Intervention: Intensive follow-up (pulmonary disease screening and follow-up at 3-month intervals)
Number of subjects: 1353

Group type: COMPARATOR
Intervention: Routine follow-up (6-month follow-up intervals with annual screening)
Number of subjects: 1353
Study: 3689629

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 28659349

Group type: EXPERIMENTAL
Intervention: Endoscopic Mucosal Resection (EMR)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Transanal Endoscopic Microsurgery (TEM)
Number of subjects: 204
Study: 26813677

Group type: EXPERIMENTAL
Intervention: G.H.3. tablets
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 25895695

Group type: EXPERIMENTAL
Intervention: Thylakoids
Number of subjects: 0
Study: 23083925

Group type: EXPERIMENTAL
Intervention: Atropine (0.04 mg/kg) administered at peak exercise during session #2
Number of subjects: 38
Study: 20813357

Group type: EXPERIMENTAL
Intervention: Day 2 embryo transfer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Day 3 embryo transfer
Number of subjects: 0
Study: 18199797

Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 16

Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 16
Study: 17023713

Group type: EXPERIMENTAL
Intervention: 500 mg DHA + 150 mg eicosapentaenoic acid, 400 microg 5‐methyl‐tetrahydrofolic acid
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: 500 mg DHA + 400 microg 5‐methyl‐tetrahydrofolic acid
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 12931301

Group type: EXPERIMENTAL
Intervention: Internal electrical cardioversion using epicardial wire electrodes with low shock energies
Number of subjects: 2

Group type: COMPARATOR
Intervention: Conventional treatment (antiarrhythmic medication, calcium channel antagonists, beta-adrenergic blockers, or amiodarone)
Number of subjects: 2

Group type: COMPARATOR
Intervention: External electrical cardioversion under general anesthesia
Number of subjects: 2
Study: 10658028

Group type: EXPERIMENTAL
Intervention: Poikilocapnic hypoxia (PH)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Isocapnic hypoxia (IH)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Normoxic voluntary hyperpnea (HP)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Normoxia (NO)
Number of subjects: 13
Study: 8638778

Group type: EXPERIMENTAL
Intervention: Aprotinin (200,000 KIU/h)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 44
Study: 1446868

Group type: EXPERIMENTAL
Intervention: MCT/LCT emulsion (50%/50%)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: LCT emulsion
Number of subjects: 35

Group type: COMPARATOR
Intervention: 5% glucose in NaCl 0.9% (Control)
Number of subjects: 35
Study: 6423840

Group type: EXPERIMENTAL
Intervention: Full-field pelvic radiation
Number of subjects: 73

Group type: COMPARATOR
Intervention: Delayed hormonal therapy
Number of subjects: 73
Study: 30520764

Group type: EXPERIMENTAL
Intervention: Serrated polyposis syndrome (SPS) diagnosis
Number of subjects: 5000

Group type: EXPERIMENTAL
Intervention: Reasons for missed SPS diagnosis
Number of subjects: 5000
Study: 29061179

Group type: EXPERIMENTAL
Intervention: Whey protein supplementation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Weight-loss diet
Number of subjects: 60
Study: 25538172

Group type: EXPERIMENTAL
Intervention: Baseline neutrophil-lymphocyte ratio (BLNLR) ≥3.0
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: Conversion from high (≥3) to low (<3) NLR
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: Baseline NLR (BLNLR)
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: Median OS
Number of subjects: 755
Study: 23656766

Group type: EXPERIMENTAL
Intervention: Continuous high-volume hemofiltration (CHVHF)
Number of subjects: 65
Study: 20833386

Group type: EXPERIMENTAL
Intervention: sidelying end‐range lumbar flexion position
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: sidelying mid‐range lumbar flexion position
Number of subjects: 41
Study: 19492924

Group type: EXPERIMENTAL
Intervention: Outpatient induction using nitric oxide donors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inpatient induction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Outpatient cervical ripening by prostaglandins or other cervical ripening agents
Number of subjects: 0
Study: 17562243

Group type: EXPERIMENTAL
Intervention: sorafenib/gemcitabine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: sorafenib/erlotinib
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: sorafenib/gemcitabine or sorafenib/erlotinib
Number of subjects: 100
Study: 15062911

Group type: EXPERIMENTAL
Intervention: Health education
Number of subjects: 30
Study: 12147029

Group type: EXPERIMENTAL
Intervention: Unmodified whole-blood-derived platelets
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Poststorage plasma-removed platelets
Number of subjects: 66

Group type: COMPARATOR
Intervention: Prestorage WBC-reduced platelets
Number of subjects: 66